San Diego-centered Viking Therapeutics marked itself as a significant competitor during the weight loss drug current market in February just after revealing promising information from a mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented like a weekly injection As well as in